Developer docs
API playgroundTry for free, no card

Search company profiles

Future Pharmaceutical industries

Full company profile

uuid000fx8a

Namestring
Future Pharmaceutical industries
Legal namestring
Future Pharmaceutical Industries
Company typeenum
Private
Founded yearint
2011
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersNew Cairo, Egypt
HQ citystring
New Cairo
HQ countrystring
Egypt
HQ regionstring
Africa
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals manufacturing, contract pharmaceutical manufacturing, pharmaceutical dosage forms, OTC dietary supplements, multinational CMO services
Industry1 code
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals Manufacturing
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Generic Pharmaceutical Manufacturing
TypeOne Time License
Description

Production and sale of generic medicines across multiple therapeutic categories including cardiovascular, anti-diabetic, CNS, pain management, antibiotics, respiratory, anti-rheumatic, and dermatology products. Revenue generated through wholesale distribution to pharmacies, hospitals, and healthcare providers.

fpi-futurepharma.com
2Contract Manufacturing Services (CMO)
TypeProfessional Services
Description

Certified contract manufacturing services for multinational pharmaceutical companies (Sanofi, Sandoz, Novartis, Abbott) requiring production under cGMP standards. FPI manufactures products on behalf of these companies in exchange for manufacturing fees or product supply agreements.

fpi-futurepharma.com
3OTC and Dietary Supplements
TypeOne Time License
Description

Over-the-counter pharmaceutical products and dietary supplements sold directly to consumers through pharmacies and retail outlets. Includes products like FPi-Zinc, Broncoxil-N Syrup, Futacare Tab, and Formicee supplements.

fpi-futurepharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Future Pharmaceutical Industries (FPI) is a cGMP-certified Egyptian pharmaceutical manufacturer that develops, manufactures, and distributes generic pharmaceutical products across multiple therapeutic categories (cardiovascular, anti-diabetic, GIT, CNS, antibiotics, respiratory, dermatology, and pain management) in diverse dosage forms including tablets, capsules, sachets, powders, liquids, semi-solids, creams, gels, and ointments. The company also produces OTC products and dietary supplements, and provides contract manufacturing services for multinational pharmaceutical companies including Sanofi, Sandoz, Novartis, and Abbott.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Secured multinational pharmaceutical manufacturing partnerships with Sanofi, Sandoz, Novartis, and Abbott through GMP certification compliance
+1 more record
Product overview1 text field

Future Pharmaceutical Industries (FPI) is a cGMP certified Egyptian pharmaceutical manufacturer producing a diversified portfolio of generic medicines across multiple therapeutic categories. The company manufactures pharmaceutical forms including tablets, capsules, sachets, powder in bottles, liquid oral, topical, semi-solid, cream, gel, and ointments. The product portfolio covers eight therapeutic areas: Orthopedic/Bone and Pain (NSAIDs like Ibuprofen and Etoricoxib), Infection (antibiotics including Cefadroxil, Moxifloxacin, Nitazoxanide), Cardio/Metabolic (antihypertensives including Candesartan and Irbesartan, statins like Rosuvastatin, antidiabetics including Metformin combinations), ENT (antihistamines like Ebastine, vestibular agents like Betahistine), Gastroenterology (PPIs including Esomeprazole, Lansoprazole, Pantoprazole), Neuro/Psychiatry (antiepileptics including Levetiracetam, Brivaracetam, antidepressants including Escitalopram, Fluoxetine, Mirtazapine, antipsychotics including Quetiapine), Sexual Dysfunction (Tadalafil), and OTC/Dietary Supplements (vitamins, zinc supplements). FPI also offers contract manufacturing services for multinational pharmaceutical companies.

Product and service1 record
1Contract Manufacturing Services (CMO)
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Abbott
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2017-01-01
Description

Abbott conducted GMP audit on FPI in 2017 and certified the facility. FPI serves as a manufacturing partner for Abbott's pharmaceutical products.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2014-03-01
Description

Novartis conducted OTC and Pharma GMP audit in March 2014 and certified FPI's manufacturing capabilities. FPI produces Novartis products as a contract manufacturing partner.

3Sandoz
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2013-12-01
Description

Sandoz certified FPI in December 2013 for pharmaceutical industries with highly complex and novel technologies. FPI provides contract manufacturing services for Sandoz products.

4EMEA (European Medicines Agency)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2013-11-01
Description

FPI received EMEA certificate in November 2013, enabling their medical products to be considered for marketing approval in countries outside the EU that reference EMEA assessments.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2013-10-01
Description

Sanofi issued FPI a GMP certificate in October 2013 recognizing outstanding quality manual and good manufacturing practices. FPI serves as a contract manufacturing partner for Sanofi, producing pharmaceutical products under their brand at FPI's cGMP-certified facility.

Strategic tierMinorTypeOthers
Description

Sabbour Construction designed FPI's manufacturing facility, which spans over 16,400 m2 in Badr City Industrial Zone, Cairo, Egypt.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Cipla is one of the world's largest generic pharmaceutical manufacturers with active presence across Africa and the Middle East. Comparable to FPI on molecule breadth, export-driven growth model, and CMO/partnering strategy with multinationals.

TypeDirect peer
Description

EVA Pharma is one of Egypt's largest domestic pharmaceutical manufacturers with a similarly diversified generic portfolio and multi-country MENA/Africa export footprint. Direct overlap on therapeutic breadth, cGMP-grade manufacturing, and CMO-style partnerships.

TypeBroad incumbent
Description

Aurobindo is a large Indian-headquartered generics manufacturer with global reach and significant CMO/formulations services. Comparable to FPI on manufacturing scale, generic breadth, and outward market strategy — though at materially larger scale.

4Julphar (Gulf Pharmaceutical Industries)
TypeRegional player
Description

Julphar is a UAE-based generic pharmaceutical manufacturer producing across multiple dosage forms and exporting across MENA. Comparable to FPI on portfolio breadth, regional distribution, and contract manufacturing ambitions.

TypeBroad incumbent
Description

Hikma is a large MENA-headquartered generic and injectable pharmaceutical manufacturer with significantly broader scale and product range than FPI. Comparable on geography, generic-and-injectable strategy, and contract manufacturing capabilities.

TypeDirect peer
Description

EIPICO is a major Egyptian generic pharmaceutical manufacturer producing tablets, capsules, injectables, and sterile products. Comparable to FPI on geography, dosage-form breadth, and target customers (Egyptian pharmacies, hospitals, and regional export).

7Egyptian Company for Cosmetics & Pharmaceuticals (ECCPA / CID)
TypeDirect peer
Description

CID is an Egyptian pharmaceutical manufacturer producing generics across multiple therapeutic categories including CNS, cardiovascular, anti-infectives, and respiratory. Direct overlap with FPI on domestic-market portfolio, dosage forms, and Egyptian regulatory positioning.

TypeDirect peer
Description

Pharco is one of the largest Egyptian pharmaceutical groups, producing generics and OTC products with strong regional exports. Directly comparable to FPI on therapeutic breadth, regional distribution, and Egyptian-market positioning.

TypeRegional player
Description

SPIMACO is a Saudi-based pharmaceutical manufacturer producing generics and serving MENA markets. Comparable to FPI on regional positioning, generic focus, and contract manufacturing for multinational partners.

TypeDirect peer
Description

Memphis is an Egyptian pharmaceutical company producing generics and OTC products with regional distribution. Comparable to FPI on Egypt-centric operations, generic-OTC portfolio mix, and similar therapeutic-category coverage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Future Pharmaceutical industries

Generic Pharmaceuticals Manufacturingfpi-futurepharma.com

Future Pharmaceutical industries firmographics

Firmographics
Name
Future Pharmaceutical industries
Legal name
Future Pharmaceutical Industries
Website
https://fpi-futurepharma.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

Future Pharmaceutical industries industry classification

Industry
Product category
Generic Pharmaceuticals Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing

Keywords

  • Generic pharmaceuticals manufacturing
  • Contract pharmaceutical manufacturing
  • Pharmaceutical dosage forms
  • OTC dietary supplements
  • Multinational CMO services

Where Future Pharmaceutical industries is headquartered

Location

Headquarters

HQ city
New Cairo
HQ country
Egypt
HQ region
Africa

Offices2 records

Markets served

Future Pharmaceutical industries business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Generic Pharmaceutical Manufacturing: Production and sale of generic medicines across multiple therapeutic categories including cardiovascular, anti-diabetic, CNS, pain management, antibiotics, respiratory, anti-rheumatic, and dermatology products. Revenue generated through wholesale distribution to pharmacies, hospitals, and healthcare providers.
  2. Contract Manufacturing Services (CMO): Certified contract manufacturing services for multinational pharmaceutical companies (Sanofi, Sandoz, Novartis, Abbott) requiring production under cGMP standards. FPI manufactures products on behalf of these companies in exchange for manufacturing fees or product supply agreements.
  3. OTC and Dietary Supplements: Over-the-counter pharmaceutical products and dietary supplements sold directly to consumers through pharmacies and retail outlets. Includes products like FPi-Zinc, Broncoxil-N Syrup, Futacare Tab, and Formicee supplements.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Future Pharmaceutical industries product offering

Product offering

Core offering

Future Pharmaceutical Industries (FPI) is a cGMP-certified Egyptian pharmaceutical manufacturer that develops, manufactures, and distributes generic pharmaceutical products across multiple therapeutic categories (cardiovascular, anti-diabetic, GIT, CNS, antibiotics, respiratory, dermatology, and pain management) in diverse dosage forms including tablets, capsules, sachets, powders, liquids, semi-solids, creams, gels, and ointments. The company also produces OTC products and dietary supplements, and provides contract manufacturing services for multinational pharmaceutical companies including Sanofi, Sandoz, Novartis, and Abbott.

Product overview

Future Pharmaceutical Industries (FPI) is a cGMP certified Egyptian pharmaceutical manufacturer producing a diversified portfolio of generic medicines across multiple therapeutic categories. The company manufactures pharmaceutical forms including tablets, capsules, sachets, powder in bottles, liquid oral, topical, semi-solid, cream, gel, and ointments. The product portfolio covers eight therapeutic areas: Orthopedic/Bone and Pain (NSAIDs like Ibuprofen and Etoricoxib), Infection (antibiotics including Cefadroxil, Moxifloxacin, Nitazoxanide), Cardio/Metabolic (antihypertensives including Candesartan and Irbesartan, statins like Rosuvastatin, antidiabetics including Metformin combinations), ENT (antihistamines like Ebastine, vestibular agents like Betahistine), Gastroenterology (PPIs including Esomeprazole, Lansoprazole, Pantoprazole), Neuro/Psychiatry (antiepileptics including Levetiracetam, Brivaracetam, antidepressants including Escitalopram, Fluoxetine, Mirtazapine, antipsychotics including Quetiapine), Sexual Dysfunction (Tadalafil), and OTC/Dietary Supplements (vitamins, zinc supplements). FPI also offers contract manufacturing services for multinational pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Contract Manufacturing Services (CMO)

Quantifiable outcome

  • Secured multinational pharmaceutical manufacturing partnerships with Sanofi, Sandoz, Novartis, and Abbott through GMP certification compliance
  • +1 more outcomes

Companies that use Future Pharmaceutical industries

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Future Pharmaceutical industries technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Future Pharmaceutical industries partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • AbbottcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2017Abbott conducted GMP audit on FPI in 2017 and certified the facility. FPI serves as a manufacturing partner for Abbott's pharmaceutical products.
  • NovartiscoreOEM/ Whitelabel/ Licensing Partner · 1 March 2014Novartis conducted OTC and Pharma GMP audit in March 2014 and certified FPI's manufacturing capabilities. FPI produces Novartis products as a contract manufacturing partner.
  • SandozcoreOEM/ Whitelabel/ Licensing Partner · 1 December 2013Sandoz certified FPI in December 2013 for pharmaceutical industries with highly complex and novel technologies. FPI provides contract manufacturing services for Sandoz products.
  • EMEA (European Medicines Agency)minorStrategic or Co-development Partner · 1 November 2013FPI received EMEA certificate in November 2013, enabling their medical products to be considered for marketing approval in countries outside the EU that reference EMEA assessments.
  • SanoficoreOEM/ Whitelabel/ Licensing Partner · 1 October 2013Sanofi issued FPI a GMP certificate in October 2013 recognizing outstanding quality manual and good manufacturing practices. FPI serves as a contract manufacturing partner for Sanofi, producing pharmaceutical products under their brand at FPI's cGMP-certified facility.
  • Sabbour ConstructionminorOthersSabbour Construction designed FPI's manufacturing facility, which spans over 16,400 m2 in Badr City Industrial Zone, Cairo, Egypt.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Future Pharmaceutical industries competitors and assessment

Company assessment

Broad incumbents

  • Cipla: Cipla is one of the world's largest generic pharmaceutical manufacturers with active presence across Africa and the Middle East. Comparable to FPI on molecule breadth, export-driven growth model, and CMO/partnering strategy with multinationals.
  • Aurobindo Pharma: Aurobindo is a large Indian-headquartered generics manufacturer with global reach and significant CMO/formulations services. Comparable to FPI on manufacturing scale, generic breadth, and outward market strategy — though at materially larger scale.
  • Hikma Pharmaceuticals: Hikma is a large MENA-headquartered generic and injectable pharmaceutical manufacturer with significantly broader scale and product range than FPI. Comparable on geography, generic-and-injectable strategy, and contract manufacturing capabilities.

Direct peers

  • EVA Pharma: EVA Pharma is one of Egypt's largest domestic pharmaceutical manufacturers with a similarly diversified generic portfolio and multi-country MENA/Africa export footprint. Direct overlap on therapeutic breadth, cGMP-grade manufacturing, and CMO-style partnerships.
  • EIPICO (Egyptian International Pharmaceutical Industries Company): EIPICO is a major Egyptian generic pharmaceutical manufacturer producing tablets, capsules, injectables, and sterile products. Comparable to FPI on geography, dosage-form breadth, and target customers (Egyptian pharmacies, hospitals, and regional export).
  • Egyptian Company for Cosmetics & Pharmaceuticals (ECCPA / CID): CID is an Egyptian pharmaceutical manufacturer producing generics across multiple therapeutic categories including CNS, cardiovascular, anti-infectives, and respiratory. Direct overlap with FPI on domestic-market portfolio, dosage forms, and Egyptian regulatory positioning.
  • Pharco Pharmaceuticals: Pharco is one of the largest Egyptian pharmaceutical groups, producing generics and OTC products with strong regional exports. Directly comparable to FPI on therapeutic breadth, regional distribution, and Egyptian-market positioning.
  • Memphis Pharmaceuticals: Memphis is an Egyptian pharmaceutical company producing generics and OTC products with regional distribution. Comparable to FPI on Egypt-centric operations, generic-OTC portfolio mix, and similar therapeutic-category coverage.

Regional players

  • Julphar (Gulf Pharmaceutical Industries): Julphar is a UAE-based generic pharmaceutical manufacturer producing across multiple dosage forms and exporting across MENA. Comparable to FPI on portfolio breadth, regional distribution, and contract manufacturing ambitions.
  • SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): SPIMACO is a Saudi-based pharmaceutical manufacturer producing generics and serving MENA markets. Comparable to FPI on regional positioning, generic focus, and contract manufacturing for multinational partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Future Pharmaceutical industries social profiles

Digital presence

Future Pharmaceutical industries compliance and trust

Trust signal

Compliance7 records

Future Pharmaceutical industries financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Future Pharmaceutical industries leadership team

Management profile

Number of profiles

Profiles1 record

Future Pharmaceutical industries funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Future Pharmaceutical industries M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Future Pharmaceutical industries

What does Future Pharmaceutical industries do?

Future Pharmaceutical Industries (FPI) is a cGMP-certified Egyptian pharmaceutical manufacturer that develops, manufactures, and distributes generic pharmaceutical products across multiple therapeutic categories (cardiovascular, anti-diabetic, GIT, CNS, antibiotics, respiratory, dermatology, and pain management) in diverse dosage forms including tablets, capsules, sachets, powders, liquids, semi-solids, creams, gels, and ointments. The company also produces OTC products and dietary supplements, and provides contract manufacturing services for multinational pharmaceutical companies including Sanofi, Sandoz, Novartis, and Abbott.

Is Future Pharmaceutical industries a public or private company?

Future Pharmaceutical industries is a private company. It is classified as private equity controlled and is currently operating.

When was Future Pharmaceutical industries founded?

Future Pharmaceutical industries was founded in 2011. It employs 501 to 1,000 people.

Where is Future Pharmaceutical industries based?

Future Pharmaceutical industries is headquartered in New Cairo, Egypt, in the Africa region.

How does Future Pharmaceutical industries make money?

Three revenue lines are on record. Generic Pharmaceutical Manufacturing is the primary driver. The others are contract Manufacturing Services (CMO) and OTC and Dietary Supplements.

Who are Future Pharmaceutical industries's main competitors?

Broad incumbents on record are Cipla, Aurobindo Pharma and Hikma Pharmaceuticals. Direct peers are EVA Pharma, EIPICO (Egyptian International Pharmaceutical Industries Company), Egyptian Company for Cosmetics & Pharmaceuticals (ECCPA / CID), Pharco Pharmaceuticals and Memphis Pharmaceuticals. Regional players are Julphar (Gulf Pharmaceutical Industries) and SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation).

Does Future Pharmaceutical industries have an API?

No public API is recorded for Future Pharmaceutical industries.

What industry is Future Pharmaceutical industries in?

Future Pharmaceutical industries's product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales